RIT with Y90-Ibritumomab Tiuxetan in Follicular Non-Hodgkin Lymphoma: Evaluation of Recent Outcomes in a Single Institution

Table 3

Disease status before ⁹⁰Y-IT therapy.

Status before treatment	Response to ^90Y-IT treatment				Total
	CR	PR	NR	NV
Relapsed	27	1	2	1	31
Consolidation	13	1	0	8	22
Refractory	3	3	1	0	7
Partial response	5	0	0	0	5
Total	48	5	3	9	65

NHL-F: Non-Hodgkin follicular lymphoma; CR: complete response; PR: partial response; NR: no response; NV: non valuable.